Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients.

ABSTRACT: OBJECTIVES:In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. NFL changes were related to disease activity. METHODS:We examined NFL levels by single-molecule array in 88 CSF, 348 plasma and 131 sera from treatment-naïve RRMS patients (n=52), healthy controls (n=23) and a placebo group matched by age, sex and NFL (n=52). Plasma/sera were collected at baseline, and 1, 3, 6 and 12 months after DMF. CSF samples were collected at baseline and 12 months after DMF. RESULTS:NFL concentration in CSF, plasma and serum correlated highly (p<0.0001 for all), but plasma l

SUBMITTER: Sejbaek T 

PROVIDER: S-EPMC6902070 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature